Pregnancy and lactation
There are no clinical data on pregnancies exposed to celecoxib. Studies in animals (rats and rabbits) have shown toxicity to reproduction including malformations (see sections cons-indications and preclinical safety data). In humans, the risk during pregnancy is unknown but can not be excluded. Like other drugs that inhibit prostaglandin synthesis, celecoxib may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester of pregnancy. Celecoxib is cons-indicated during pregnancy and in women who may become pregnant (see cons-indications and warnings and precautions for use). If a woman becomes pregnant during treatment, celecoxib should be discontinued.
There are no studies on the excretion of celecoxib in human breast milk. Celecoxib is excreted in the milk of lactating rats at concentrations similar to those found in plasma. Women who take celecoxib should not breastfeed.